Answers are grounded in this paper and cite their sources.
Streptogramin antibiotics are mixtures of two chemically unrelated A and B compounds that act synergistically in vivo against gram-positive pathogens, such as staphylococci, streptococci, and enterococci (8, 11). Resistance against B compounds is very widespread among enterococci and is mediated via the ermBgene cluster (e.g., on Tn917) that confers macrolide-lincosamide-streptogramin B resistance (7). The synergistic mixture of streptogramins A and B overcomes resistance to B compounds but is inactive in resistance to A compounds. The only known resistance mechanism against streptogramin A compounds in enterococci is mediated by the streptogramin acetyltransferase SatA (9). Enterococcus faecium isolates withsatA-mediated resistance have been found in samples of human and animal origins, indicating a possible spread of resistance genes or resistant bacteria among different ecosystems (10).Fig. 1.A 904-bp sequence located on the 5.5-kbp cloned fragment in pUC18 (GenBank accession no. AF139725). The ORF begins at nucleotide 63 with an ATG start codon preceding a putative ribosomal binding site (RBS) (double-underlined) at positions 50 to 57. The predicted gene sequence encodes a protein of 214 aa which shows significant homology with other streptogramin acetyltransferases (aa motifs I, II, III; see also Fig. 2). The locations of the primers satG1 and satG2, specific only for the satG sequence, are underlined (plus strand).
No takes yet. Share an insight, caveat, or question.
Werner et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: